A 2026 DIVERGE analysis of 3,677 antidepressant-exposed patients with major depressive disorder in Pakistan classified 34% as treatment resistant, while 86% received psychotropic polypharmacy and only 6% received psychotherapy.1 The CYP2C19 signal is real enough to study prospectively, but the main treatment-system finding is medication stacking in a setting where psychological care was rare. Research …
A 12-week randomized pilot trial in 60 Veterans with depression and psychiatric polypharmacy found that 30% had an actionable antidepressant gene-drug interaction, but immediate access to pharmacogenomic results did not clearly change prescribing or Patient Health Questionnaire-9 depression scores compared with delayed access.1 Research Highlights Actionable PGx results were common: 18 of 60 Veterans, or …
A 2026 methylome-wide association study by Shen et al. found 48 CpG methylation sites tied to the quadratic CYP2C19 metabolizer-status term in 18,396 Generation Scotland participants, with 19 sites showing non-linear patterns and targeted replication in 1,238 older adults.1 That supports CYP2C19 as real biology beneath SSRI pharmacogenomics, but it does not prove universal antidepressant …
Amitriptyline (brand name “Elavil”) is a drug derived from the chemical dibenzocycloheptadiene that was discovered and approved in the early 1960s for the treatment of major depression. It is formally classified as a tricyclic antidepressant (TCA) and functions principally via inhibiting the presynaptic reuptake of norepinephrine and serotonin. This effect of dual presynaptic reuptake inhibition …
Soma (Carisoprodol) is a drug developed in the late 1950s that was initially suspected to be an antiseptic, but turned out to be a CNS depressant with minor muscle-relaxant properties. Although its mechanism of action isn’t fully elucidated, carisoprodol and its primary metabolite “meprobamate” are believed to indirectly modulate the neurotransmission of GABA (gamma-aminobutyric-acid) via …